Record-breaking performance and optimistic forecast drive stock rally

  • Eli Lilly’s stock surges to a fifth-straight record close
  • Fourth-quarter earnings beat expectations
  • 16% jump in prices contributes to strong performance
  • Upbeat 2024 revenue outlook
  • Net income rises to $2.19 billion
  • Adjusted earnings per share of $2.49 beat consensus
  • Revenue jumps 28.1% to $9.35 billion
  • Sales of obesity drug Zepbound total $175.8 million
  • No recorded sales of Covid-19 antibodies
  • 2024 adjusted EPS expected to be $12.20 to $12.70
  • 2024 revenue expected to be $40.4 billion to $41.6 billion
  • Stock has risen 18.7% over the past three months

Shares of Eli Lilly and Co. soared to a fifth-straight record close after the company reported better-than-expected fourth-quarter earnings. The strong performance was fueled by a 16% increase in prices, contributing to a 28.1% jump in revenue to $9.35 billion. Net income rose to $2.19 billion, surpassing the previous year’s figures. Adjusted earnings per share of $2.49 also exceeded consensus estimates. Sales of the company’s obesity drug Zepbound reached $175.8 million, while no sales of Covid-19 antibodies were recorded. Looking ahead, Eli Lilly expects adjusted EPS of $12.20 to $12.70 and revenue of $40.4 billion to $41.6 billion for 2024, surpassing expectations. The stock has seen significant growth, rising 18.7% over the past three months.

Public Companies: Eli Lilly and Co. (LLY)
Private Companies:
Key People:

Track all markets on TradingView

Factuality Level: 8
Justification: The article provides specific information about Eli Lilly and Co.’s fourth-quarter earnings, including net income, adjusted earnings per share, and revenue. It also mentions the sales of the company’s obesity drug and Covid-19 antibodies. The information is supported by data from FactSet. However, the article does not provide any opposing viewpoints or potential risks, which could affect the overall factuality level.

Noise Level: 3
Justification: The article provides relevant information about Eli Lilly and Co.’s fourth-quarter earnings, including net income, adjusted earnings per share, and revenue. It also mentions the company’s expectations for 2024. However, the article lacks in-depth analysis, scientific rigor, and intellectual honesty. It does not explore the consequences of the company’s actions or hold powerful people accountable. Additionally, it does not provide actionable insights or solutions for the reader. Overall, the article contains mostly factual information without much analysis or critical thinking.

Financial Relevance: Yes
Financial Markets Impacted: Shares of Eli Lilly and Co.

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to financial topics as it discusses the fourth-quarter earnings of Eli Lilly and Co. and provides an outlook for future revenue. There is no mention of an extreme event.

Reported publicly: www.marketwatch.com